Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,128.88 | 72.00 | -0.88% |
| DAX 40 | 23,999.76 | 119.13 | -0.49% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,708.27 | 51.79 | -0.53% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |